These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31019610)

  • 21. Solid pseudopapillary tumour should be part of differential diagnosis of focal pancreatic lesions with increased
    Somme F; Montaz-Rosset MS; Averous G; Deur J; Goichot B; Bachellier P; Addeo P; Imperiale A
    Clin Endocrinol (Oxf); 2020 Jul; 93(1):78-81. PubMed ID: 32314437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens.
    Ma C; Yang P; Li J; Bian Y; Wang L; Lu J
    Abdom Radiol (NY); 2020 Mar; 45(3):782-788. PubMed ID: 31292672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.
    Casadonte R; Kriegsmann M; Perren A; Baretton G; Deininger SO; Kriegsmann K; Welsch T; Pilarsky C; Kriegsmann J
    Proteomics Clin Appl; 2019 Jan; 13(1):e1800046. PubMed ID: 30548962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics.
    He M; Liu Z; Lin Y; Wan J; Li J; Xu K; Wang Y; Jin Z; Tian J; Xue H
    Eur J Radiol; 2019 Aug; 117():102-111. PubMed ID: 31307634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study.
    Jeon SK; Lee JM; Joo I; Lee ES; Park HJ; Jang JY; Ryu JK; Lee KB; Han JK
    Radiology; 2017 Jul; 284(1):77-87. PubMed ID: 28092495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
    Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
    Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
    Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
    AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
    [No Abstract]   [Full Text] [Related]  

  • 28. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma.
    Ha J; Choi SH; Byun JH; Kim KW; Kim SY; Kim JH; Kim HJ
    Eur Radiol; 2021 May; 31(5):3427-3438. PubMed ID: 33146798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
    Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
    Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypervascular lesions of the pancreas: Think before you act.
    Wcislak SM; Stiles ZE; Deneve JL; Glazer ES; Behrman SW; Farooq FT; Dickson PV
    Am J Surg; 2019 Aug; 218(2):362-367. PubMed ID: 30509457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour.
    Kim DW; Kim HJ; Kim KW; Byun JH; Song KB; Kim JH; Hong SM
    Eur Radiol; 2015 May; 25(5):1375-83. PubMed ID: 25465713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of pancreatic ductal adenocarcinoma from other neoplastic solid pancreatic lesions: a tertiary oncology center experience.
    Krishna SG; Li F; Bhattacharya A; Ladha H; Porter K; Singh A; Ross WA; Bhutani MS; Lee JH
    Gastrointest Endosc; 2015 Feb; 81(2):370-9. PubMed ID: 25442085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings.
    Choi SY; Kim SH; Kang TW; Song KD; Park HJ; Choi YH
    AJR Am J Roentgenol; 2016 Feb; 206(2):291-300. PubMed ID: 26797355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of mass-forming focal pancreatitis from pancreatic ductal adenocarcinoma: value of characterizing dynamic enhancement patterns on contrast-enhanced MR images by adding signal intensity color mapping.
    Kim M; Jang KM; Kim JH; Jeong WK; Kim SH; Kang TW; Kim YK; Cha DI; Kim K
    Eur Radiol; 2017 Apr; 27(4):1722-1732. PubMed ID: 27510628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodel magnetic resonance imaging of mass-forming autoimmune pancreatitis: differential diagnosis with pancreatic ductal adenocarcinoma.
    Jia H; Li J; Huang W; Lin G
    BMC Med Imaging; 2021 Oct; 21(1):149. PubMed ID: 34654379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing.
    Yao J; Shi Y; Cao K; Lu L; Lu J; Song Q; Jin G; Xiao J; Hou Y; Zhang L
    Med Image Anal; 2021 Oct; 73():102150. PubMed ID: 34303891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade.
    Guo C; Zhuge X; Wang Z; Wang Q; Sun K; Feng Z; Chen X
    Abdom Radiol (NY); 2019 Feb; 44(2):576-585. PubMed ID: 30182253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Staging accuracy of MR for pancreatic neuroendocrine tumor and imaging findings according to the tumor grade.
    Kim JH; Eun HW; Kim YJ; Han JK; Choi BI
    Abdom Imaging; 2013 Oct; 38(5):1106-14. PubMed ID: 23728305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
    Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
    Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
    Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.